Entera Bio Ltd. announced positive preclinical data supporting the development of a long-acting parathyroid hormone (PTH) analog for hypoparathyroidism. The proprietary analog achieved longer plasma half-life and sustained calcium elevation for over three days. Hypoparathyroidism is a rare endocrine disorder treated with daily injections. Entera aims to develop a once-daily tablet. In vitro and in vivo validation studies showed a longer plasma half-life of the lead variant compared to controls. Serum calcium levels increased for more than three days with the lead variant, while controls did not increase levels. Entera plans to present these findings at an upcoming medical conference.

Read more at GlobeNewswire: Entera Bio Announces New Data Supporting Further